The recent decision by the Central government to waive duties on critical petrochemical products has received a positive response from industry leaders. This action, taken on April 1, 2026, is part of the government’s strategy to facilitate timely movement of goods amidst the ongoing conflict in West Asia. Experts believe that this proactive measure will help ease the pressure caused by disruptions in the supply chain.

The Indian Pharmaceutical Alliance has specifically acknowledged the government’s initiative. Sudarshan Jain, the Secretary General, highlighted the challenges posed by the conflict, including increases in energy costs and freight charges, which could delay essential product deliveries. He expressed appreciation for the government’s efforts to address these challenges through effective coordination and the establishment of Empowered Committees of Secretaries.

According to Jain, the industry’s primary concern is to ensure the seamless supply of medicines, which is crucial for public health. He noted that the restoration of the Remission of Duties and Taxes on Exported Products (RoDTEP) to its previous rates, along with the duty waiver, is vital for maintaining the supply chain in the pharmaceutical sector.

Industry Leaders Acknowledge Timely Support

Prominent figures within the industry have welcomed the government’s decision, labelling it a timely intervention. Himanshu Baid, Managing Director of Poly Medicure Ltd, commented on the significance of raw materials such as Polycarbonate and PVC resin. These materials, exempt from duties, are essential for the production of medical consumables, and their availability will provide substantial support to manufacturers.

Baid expressed gratitude to the Indian government, particularly the Ministry of Finance and the Ministry of Commerce and Industry, for facilitating these changes. He noted that the exemption of raw materials would alleviate challenges faced by domestic manufacturers, particularly in the micro, small, and medium enterprises (MSME) sector.

Moreover, Baid emphasised the importance of restoring the RoDTEP rates, which had previously been reduced by 50 per cent. He considers this adjustment as crucial for enhancing the competitiveness of Indian medical devices in the international market, potentially fostering export growth.

Comprehensive Benefits for the Pharmaceutical Sector

Nikkhil K Masurkar, CEO of ENTOD Pharmaceuticals, also expressed approval of the duty waiver on key petrochemical inputs. He stated that materials such as Polypropylene, Polyethene, PVC, and PET are integral to developing pharmaceutical packaging and delivery systems. The reduction in input costs, he noted, will positively influence product quality, supply reliability, and medicine affordability.

Masurkar pointed out that the restoration of RoDTEP rates is an encouraging development that would fortify India’s position in global pharmaceuticals. He highlighted the significance of these rates in boosting export competitiveness, asserting that it underscores India’s ability to produce high-quality medicines efficiently.

In summary, industry experts regard the Centre’s recent measures as beneficial steps towards stabilising the pharmaceutical supply chain and enhancing the overall resilience of the sector during challenging times. The decision is seen as a means to ensure uninterrupted access to essential medicines for the public while supporting manufacturers significantly.

Long or Short, get news the way you like. No ads. No redirections. Download Newspin and Stay Alert, The CSR Journal Mobile app, for fast, crisp, clean updates!

App Store –  https://apps.apple.com/in/app/newspin/id6746449540 

Google Play Store – https://play.google.com/store/apps/details?id=com.inventifweb.newspin&pcampaignid=web_share